n cohort | n CAP cases | PY | IR per 100,000 PY | Lower 95% CI | Upper 95% CI | |
---|---|---|---|---|---|---|
Lung cancer | ||||||
Crude IR | 11,837 | 1945 | 13,444 | 14,467.4 | 13,831.5 | 15,125.0 |
Standardized IRa | 1,256,235 | 13,188,819 | 9525.0 | 9508.4 | 9541.7 | |
Hematological malignancies | ||||||
Crude IR | 15,317 | 1002 | 33,662 | 2976.7 | 2795.2 | 3166.8 |
Standardized IRa | 255,193 | 13,188,819 | 1934.9 | 1927.4 | 1942.4 | |
Cancer of the gastro-intestinal tract | ||||||
Crude IR | 27,423 | 926 | 58,752 | 1576.1 | 1476.2 | 1681.0 |
Standardized IRa | 108,308 | 13,188,819 | 821.2 | 816.3 | 826.1 | |
Renal cancer & cancer of the urinary tract | ||||||
Crude IR | 13,197 | 532 | 29,431 | 1807.6 | 1657.3 | 1968.0 |
Standardized IRa | 112,611 | 13,188,819 | 853.8 | 848.9 | 858.8 | |
Control cohort (overall) | ||||||
Crude IR | 3,192,611 | 59,581 | 13,188,819 | 451.8 | 448.1 | 455.4 |
Breast cancer | ||||||
Crude IR | 22,450 | 534 | 57,359 | 931.0 | 853.7 | 1013.4 |
Standardized IRa | 45,855 | 6,647,290 | 689.8 | 683.5 | 696.2 | |
Control cohort (breast cancer) | ||||||
Crude IR | 1,604,248 | 27,154 | 6,647,290 | 408.5 | 403.7 | 413.4 |